PBA

Paradigm Biocapital Advisors Portfolio holdings

AUM $4.89B
1-Year Est. Return 251.12%
This Fund
S&P 500
This Quarter Est. Return
1 Year Est. Return
+251.12%
3 Year Est. Return
5 Year Est. Return
10 Year Est. Return
AUM
$3.73B
AUM Growth
+$355M
Cap. Flow
Cap. Flow %
Top 10 Hldgs %
Holding
42
New
Increased
Reduced
Closed

Top Buys

1
+$100M
2
+$85.8M
3
+$47.7M
4
LXEO icon
Lexeo Therapeutics
LXEO
+$43.5M
5
SRRK icon
Scholar Rock
SRRK
+$39.5M

Top Sells

1
+$412M
2
+$107M
3
+$71.4M
4
ALKS icon
Alkermes
ALKS
+$51.6M
5
LENZ
LENZ Therapeutics
LENZ
+$50M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASMB icon
26
Assembly Biosciences
ASMB
$485M
$22.6M 0.61%
+665,251
ORIC icon
27
Oric Pharmaceuticals
ORIC
$789M
$19.6M 0.53%
+2,401,217
IVA
28
Inventiva
IVA
$855M
$18.6M 0.5%
+4,000,000
KLRS
29
Kalaris Therapeutics
KLRS
$111M
$5.91M 0.16%
+700,000
AGIO icon
30
Agios Pharmaceuticals
AGIO
$1.58B
– –
-2,673,555
ALKS icon
31
Alkermes
ALKS
$6.89B
– –
-1,719,334
AMLX icon
32
Amylyx Pharmaceuticals
AMLX
$1.48B
– –
-1,900,000
COGT icon
33
Cogent Biosciences
COGT
$5.6B
– –
-3,156,398
DYN icon
34
Dyne Therapeutics
DYN
$2.85B
– –
-1,898,950
GPCR icon
35
Structure Therapeutics
GPCR
$2.64B
– –
-372,869
IRON icon
36
Disc Medicine
IRON
$2.6B
– –
-247,716
JANX icon
37
Janux Therapeutics
JANX
$840M
– –
-2,920,258
MRUS
38
DELISTED
Merus
MRUS
– –
-4,373,770
PHVS icon
39
Pharvaris
PHVS
$2.03B
– –
-1,835,494
TNGX icon
40
Tango Therapeutics
TNGX
$3.11B
– –
-3,086,184
XBI icon
41
State Street SPDR S&P Biotech ETF
XBI
$7.78B
– –
0
LENZ
42
LENZ Therapeutics
LENZ
$224M
– –
-1,073,461
1
2